HDE Market Entry and Humanitarian Use Device Designation

1. Key takeaways

Market entry under the Humanitarian Device Exemption (HDE) proceeds in two steps: first, obtain Humanitarian Use Device (HUD) designation from FDA’s Office of Orphan Products Development (OOPD); second, submit an HDE application to CDRH, CBER, or CDER. The population threshold requires that the disease or condition the device is intended to treat or diagnose affects or manifests in not more than 8,000 individuals in the United States each year.

• The 8,000 threshold is the result of a statutory amendment, not an internal FDA working assumption.
• The HDE approval standard is probable benefit, not reasonable assurance of effectiveness; the demonstration of effectiveness is waived.
• HDE-approved devices may be used only in facilities with Institutional Review Board (IRB) oversight, and profit restrictions apply.
• OOPD must act on a HUD designation request within 45 days of receipt, and the HDE review is 75 FDA days.
• HDE application numbering can be traced to the accepting center: CDRH numbers begin with H plus six digits, CBER numbers begin with BH.

2. Legal basis

The table below records the statutory section, the implementing regulation and its amendment history, the statutory threshold change, and the procedural time limits for the HUD and HDE route, all verified in 2026.

3. Expert insights

Insight 1: The 8,000 figure is the result of a legislative amendment, not an internal FDA convention. Under 21 CFR 814.100(b), as amended by 82 FR 26349 on 2017-06-07, and under FD&C Act §520(m), the threshold reads “not more than 8,000”. The earlier regulatory text referred to fewer than 4,000 individuals. Section 3052 of the 21st Century Cures Act, enacted on 2016-12-13, accomplished this increase. Content that still cites the old threshold needs updating, and citations should always carry the current statutory language rather than the superseded figure.

Insight 2: The HDE approval standard is probable benefit, not reasonable assurance of effectiveness. FDA’s official comparison table is explicit: PMA requires reasonable assurance of safety plus reasonable assurance of effectiveness, while an HDE requires that the device not expose patients to an unreasonable or significant risk of illness or injury, together with a demonstration of probable benefit, and the demonstration of effectiveness is waived. This is the key dividing line between the HDE and the PMA, and it dictates how the entire dossier should be argued.

Insight 3: The HDE carries two additional conditions that have no PMA counterpart. According to FDA’s official comparison table, devices approved under an HDE may be used only in facilities with Institutional Review Board (IRB) oversight, and profit restrictions apply. PMA-approved devices carry no such restrictions. These two conditions shape commercialization strategy, since distribution, pricing, and site selection must all be designed around them from the start rather than accommodated after approval.

Insight 4: HDE application numbering can be traced back to the accepting center. CDRH HDE numbers begin with the letter H followed by six digits (for example, H180001 is the first application received in 2018); CBER numbers begin with BH. The first two digits encode the year of receipt, and the last four digits are the sequential number for that year. Reading the number therefore tells the reviewer which center accepted the file and when it arrived.

The combined effect of these points is that an HDE program lives or dies on the quality of its population arithmetic and on disciplined sequencing. The population evidence must stand on sources a reviewer will respect, the two statutory clocks must be planned as distinct phases rather than merged, and the dossier must be argued to its own standard instead of importing PMA-style effectiveness reasoning that the HDE framework deliberately does not require. Programs that respect these boundaries reach approval with fewer cycles and with commercialization plans that already accommodate the IRB and profit constraints.

4. Practical recommendations

• Do the population calculation first: use authoritative literature, textbooks, specialty society proceedings, or government statistical publications to demonstrate that no more than 8,000 individuals are affected in the United States each year; for diagnostic devices, demonstrate that no more than that number of patients receive the diagnosis annually.
• Schedule the two steps separately: the HUD designation phase has a 45-day processing limit, and the HDE review is 75 FDA days.
• Argue the dossier along the probable benefit standard, and do not organize it to PMA-style effectiveness strength.
• Engage the using institutions on IRB oversight arrangements early.
• If the device has additional uses beyond the humanitarian use, a separate PMA or 510(k) must be submitted for those uses.

5. Verification checklist

• □ Literature-based justification of the annual US patient population completed (≤8,000 individuals).
• □ Confirmed that no comparable device for the same use is otherwise on the market.
• □ HUD designation request submitted to OOPD with mailing or delivery receipt retained.
• □ Schedule built on the 45-day HUD processing limit and the 75 FDA day HDE review limit.
• □ IRB oversight arrangements planned.
• □ Determined whether non-humanitarian uses exist; if so, a PMA or 510(k) is planned for them.
• □ Distribution, pricing, and site selection reviewed against the profit restrictions and IRB facility requirements.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com